N E W S B Y T E S
Illumina to establish Global Capability Center in Bengaluru
Illumina Inc . has announced plans to open a Global Capability Center in Bengaluru , India , to expand its technology workforce and support its global customer base . The announcement was made at the Illumina India Genomics Summit in Bengaluru . Illumina , a leader in DNA sequencing and array-based technologies , will hire 100 technology professionals in 2024 , including software engineers and IT experts , with plans to increase this number to 200 by the end of 2025 . This new center will join Illumina ’ s existing Global Capability Centers in cities such as Singapore , Cambridge , and Shanghai .
The company recently opened an Illumina Solutions Center in Bengaluru , featuring a state-of-the-art genomics lab and training facilities . Gretchen Weightman , Illumina ’ s senior vice president for the Asia-Pacific , Middle East & Africa region , emphasized the importance of genomics in public health and the strategic benefits of expanding in India . The summit also highlighted advancements and collaborations in the genomics field .
Biocon Biologics to commercialize Biosimilar Bmab 1200 in Europe , UK , Canada & Japan
Biocon Biologics has reached a settlement and license agreement with Janssen Biotech Inc ., Janssen Sciences Ireland , and Johnson & Johnson to commercialize its biosimilar Bmab 1200 , a proposed alternative to Stelara ®, in Europe , the UK , Canada , and Japan . This agreement resolves patent disputes and allows Biocon to enter these markets , with regulatory filings currently under review .
Previously , Biocon secured a settlement in the U . S . for Bmab 1200 ' s launch by February 22 , 2025 , pending FDA approval . The FDA has accepted Biocon ’ s Biologics License Application for review . Biocon Biologics has already commercialized eight biosimilars in major markets and has 12 additional biosimilar assets in development .
08
BioVoiceNews | October 2024